At least 32 subjects will be enrolled i n Cohort 1 and up to 28 subjects will be enrolled in Cohort 2. The expansion cohort of up to 44 additional subjects, including subjects receiving Cy one day prior to CRS -207 (Cohort 2) is intended to obtain additional safety, immune and efficacy data for future study planning. The expansion sample size is based on practical rather than statistical considerations. These data will be summarized in tables listing the mean, standard deviation, median, minimum, maximum, and number of subjects in a group for continuous data; in tables listing count and percentage for categorical data; and median and standard error for time -to-event data. Data will be listed for each subject. Statistical analyses will be performed and data appendices will be created by using SAS. The effects of noncompliance, dropouts, and covariates will be assessed to determine the impact on the general applicability of results from this study . Efficacy analyses will be conducted on the full analysis set and per protocol analysis set. Th e full analysis set will consist of all subjects who receive at least one dose of any study treatment . The per protocol analysis set will consist of all subjects with MPM who receive the initial 2 prime vaccinations with CRS -207 (with or without Cy) and at least 4 cycles of pemetrexed and cisplatin. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page xii TABLE OF CONTENTS Page STUDY SYNOPSIS .............................................................................................................................................. iii LIST OF FIGURES AND TABLES ....................................................................................................................